King Pharmaceuticals Inc Stock Performance
| KG Stock | 22.92 0.18 0.78% |
On a scale of 0 to 100, KING PHARMACEUTICALS holds a performance score of 5. The company secures a Beta (Market Risk) of 1.38, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, KING PHARMACEUTICALS will likely underperform. Please check KING PHARMACEUTICALS's treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to make a quick decision on whether KING PHARMACEUTICALS's current price movements will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in KING PHARMACEUTICALS INC are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly inconsistent technical and fundamental indicators, KING PHARMACEUTICALS reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.78) | Five Day Return (7.32) | Year To Date Return (16.62) | Ten Year Return 35.62 | All Time Return 129.2 |
Last Split Factor 1:20 | Last Split Date 2025-05-28 |
1 | Rafael Holdings Launches 25M Rights Offering Key Dates and Terms Investors Must Know - Stock Titan | 05/05/2025 |
2 | Insider Trading | 05/27/2025 |
3 | Meitheal Pharmaceuticals Announces Launch of Generic Paclitaxel Formulation in the United States Through Exclusive Commercial Licensing Agreement - BioSpace | 05/29/2025 |
4 | Ricks Is the King of Pharma, Thanks to Lillys Zepbound - Barrons | 06/20/2025 |
5 | Trumps 200 percent drug tariffs are ineffective The 450 billion drug king is soaring against the market - | 07/09/2025 |
6 | CNS Pharmaceuticals Inc. Stock Analysis and Forecast - Free Investment Risk Control - Jammu Links News | 07/18/2025 |
| Begin Period Cash Flow | 5.6 M | |
| Free Cash Flow | -1.3 M |
KING PHARMACEUTICALS Relative Risk vs. Return Landscape
If you would invest 2,000 in KING PHARMACEUTICALS INC on April 21, 2025 and sell it today you would earn a total of 292.00 from holding KING PHARMACEUTICALS INC or generate 14.6% return on investment over 90 days. KING PHARMACEUTICALS INC is generating 0.5446% of daily returns and assumes 8.5749% volatility on return distribution over the 90 days horizon. Put differently, 76% of stocks are less risky than KING on the basis of their historical return distribution, and some 90% of all equities are expected to be superior in generating returns on investments over the next 90 days. Expected Return |
| Risk |
KING PHARMACEUTICALS Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for KING PHARMACEUTICALS's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as KING PHARMACEUTICALS INC, and traders can use it to determine the average amount a KING PHARMACEUTICALS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0635
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | KG | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.57 actual daily | 76 76% of assets are less volatile |
Expected Return
| 0.54 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 5 95% of assets perform better |
Based on monthly moving average KING PHARMACEUTICALS is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of KING PHARMACEUTICALS by adding it to a well-diversified portfolio.
KING PHARMACEUTICALS Fundamentals Growth
KING Stock prices reflect investors' perceptions of the future prospects and financial health of KING PHARMACEUTICALS, and KING PHARMACEUTICALS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on KING Stock performance.
| Current Valuation | 223.77 M | ||||
| Shares Outstanding | 9.94 M | ||||
| Price To Earning | 32.29 X | ||||
| Price To Book | 60.07 X | ||||
| Price To Sales | 43.40 X | ||||
| Revenue | 5.25 M | ||||
| EBITDA | 141.76 K | ||||
| Net Income | 324.27 K | ||||
| Cash And Equivalents | 545.31 M | ||||
| Cash Per Share | 1.58 X | ||||
| Total Debt | 244.12 K | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 2.27 X | ||||
| Cash Flow From Operations | (1.27 M) | ||||
| Earnings Per Share | 0.03 X | ||||
| Market Capitalization | 227.81 M | ||||
| Total Asset | 4.7 M | ||||
| Retained Earnings | 947.82 M | ||||
| Working Capital | 3.74 M | ||||
| Current Asset | 1.13 B | ||||
| Current Liabilities | 496.9 M | ||||
About KING PHARMACEUTICALS Performance
By analyzing KING PHARMACEUTICALS's fundamental ratios, stakeholders can gain valuable insights into KING PHARMACEUTICALS's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if KING PHARMACEUTICALS has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if KING PHARMACEUTICALS has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.07 | 0.07 | |
| Return On Capital Employed | 0.04 | 0.04 | |
| Return On Assets | 0.07 | 0.07 |
Things to note about KING PHARMACEUTICALS INC performance evaluation
Checking the ongoing alerts about KING PHARMACEUTICALS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for KING PHARMACEUTICALS INC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| KING PHARMACEUTICALS is way too risky over 90 days horizon | |
| KING PHARMACEUTICALS appears to be risky and price may revert if volatility continues | |
| KING PHARMACEUTICALS INC was previously known as MHLD Old and was traded on NASDAQ Exchange under the symbol MHLD. | |
| KING PHARMACEUTICALS INC reports about 545.31 M in cash with (1.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58. | |
| Latest headline from news.google.com: CNS Pharmaceuticals Inc. Stock Analysis and Forecast - Free Investment Risk Control - Jammu Links News |
- Analyzing KING PHARMACEUTICALS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether KING PHARMACEUTICALS's stock is overvalued or undervalued compared to its peers.
- Examining KING PHARMACEUTICALS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating KING PHARMACEUTICALS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of KING PHARMACEUTICALS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of KING PHARMACEUTICALS's stock. These opinions can provide insight into KING PHARMACEUTICALS's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for KING Stock analysis
When running KING PHARMACEUTICALS's price analysis, check to measure KING PHARMACEUTICALS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy KING PHARMACEUTICALS is operating at the current time. Most of KING PHARMACEUTICALS's value examination focuses on studying past and present price action to predict the probability of KING PHARMACEUTICALS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move KING PHARMACEUTICALS's price. Additionally, you may evaluate how the addition of KING PHARMACEUTICALS to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |